- Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data TranscriptFeb 08, 2024
- Adverum Biotechnologies Inc at HC Wainwright Ophthalmology Virtual Conference TranscriptAug 16, 2023
- Adverum Biotechnologies Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Adverum Biotechnologies Inc ADVM-022 Update Call TranscriptJul 22, 2021
- Q4 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMar 01, 2021€107 (+7.00%)Earnings
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptNov 14, 2020
- Q2 2020 Adverum Biotechnologies Inc Earnings Call TranscriptAug 10, 2020€150 (-3.85%)Earnings
- Adverum Biotechnologies Inc Annual Shareholders Meeting TranscriptJun 23, 2020
- Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Q1 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMay 28, 2020€186 (+2.76%)Earnings
- Adverum Biotechnologies Inc to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD Call TranscriptMay 04, 2020
- Q4 2019 Adverum Biotechnologies Inc Earnings Call TranscriptMar 12, 2020€69 (-16.87%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptFeb 09, 2020
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Adverum Biotechnologies Inc Earnings Call TranscriptNov 07, 2019€72 (+2.13%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial TranscriptOct 12, 2019
- Adverum Biotechnologies Inc to Review Data Presented at Retina Society 2019 Conference Call TranscriptSep 12, 2019
- Q2 2019 Adverum Biotechnologies Inc Earnings Call TranscriptAug 08, 2019€107.02 (+2.47%)Earnings
Q4 2020 Adverum Biotechnologies Inc Earnings Call Transcript
Good afternoon, and welcome to the Adverum Biotechnologies conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand the call over to Myesha Lacy, Vice President of Investor Relations and Corporate Communications of Adverum. Please go ahead.
Thank you, Anastasia, and welcome, everyone. Today, we issued a press release to share our development planning for ADVM-022 for our wet age-related macular degeneration, or wet AMD program, recent business progress and our fourth quarter 2020 financial results. A copy of this announcement is available on the Press Releases page of the Investor Relations section of our corporate website, www.adverum.com. Please note that a replay of today's call will also be available on the Events and Presentations section of our website.
Joining me today is Dr. Laurent Fischer, Chief Executive Officer; Leone
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)